Abstract:In the era of precision medicine, genetic test results have become increasingly relevant in the care of patients with Parkinson's disease (PD) and their families. While large PD research consortia are performing widespread research genetic testing to accelerate discoveries, debate continues about whether, and to what extent, the results should be returned to patients. Ethically, it is imperative to keep participants informed, especially when findings are potentially actionable. However, research testing may not hold the same standards required from clinical diagnostic laboratories and hold significant psychosocial implications. The absence of universally recognized protocols complicates the establishment of appropriate guidelines. Aiming to develop recommendations on return of research results (RoR) practice within the Global Parkinson's Genetics Program (GP2), we conducted a global survey to gain insight on GP2 members' perceptions, practice, readiness, and needs surrounding RoR. GP2 members (n=191), representing 147 institutions and 60 countries across six continents, completed the survey. Access to clinical genetic testing services was significantly higher in high-income countries compared to low- and middle-income countries (96.6% vs. 58.4%), where funding was predominantly covered by patients themselves. While 92.7% of the respondents agreed that genetic research results should be returned, levels of agreement were higher for clinically relevant results relating to pathogenic or likely pathogenic variants in genes known to cause PD or other neurodegenerative diseases. Less than 10% offered separate clinically-accredited genetic testing before returning genetic research results. 48.7% reported having a specific statement on RoR policy in their ethics consent form, while 53.9% collected data on participants' preferences on RoR prospectively. 24.1% had formal genetic counselling training. Notably, the comfort level in returning incidental genetic findings or returning results to unaffected individuals remains low. Given the differences in resources and training for RoR, as well as ethical and regulatory considerations, tailored approaches are required to ensure equitable access to RoR. Several identified strategies to enhance RoR practices include improving informed consent processes, increasing capacity for genetic counselling including providing counselling toolkits for common genetic variants, broadening access to sustainable clinically-accredited testing, building logistical infrastructure for RoR processes, and continuing public and healthcare education efforts on the important role of genetics in PD.

Awareness, experiences and perceptions regarding genetic testing and the return of genetic and genomics results in a hypothetical research context among patients in Uganda: a qualitative study

Perceptions and beliefs of community gatekeepers about genomic risk information in African cleft research

Genetic Testing Experiences of People Living with Inherited Retinal Degenerations: Results of a Global Survey

Participant recall and understandings of information on biobanking and future genomic research: experiences from a multi-disease community-based health screening and biobank platform in rural South Africa

Understanding of Critical Elements of Informed Consent in Genomic Research: A Case of a Paediatric HIV-TB Research Project in Uganda

Evaluation of a two-step model of opportunistic genomic screening

Global Perspectives on Returning Genetic Research Results in Parkinson's Disease

Knowledge of genetic eye diseases and genetic services and attitudes toward genetic testing and gene therapy

Attitudes, knowledge, and risk perceptions of patients who received elective genomic testing as a clinical service

Genetic testing in psychiatry, the perceptions of healthcare workers and patients: a mini review

Informed consent in cancer clinical care: Perspectives of healthcare professionals on information disclosure at a tertiary institution in Uganda

Parents' and patients' perspectives, experiences, and preferences for germline genetic or genomic testing of children with cancer: A systematic review

Evolving perspectives on genetic discrimination in health insurance among health care providers

A qualitative study of the experiences of patients with prostate cancer when receiving negative genetic results: "I still don't have a grasp of what it all means"

A survey on awareness, knowledge and preferences toward genetic testing among the United States general public

Knowledge, attitudes, and practices of primary healthcare practitioners in low- and middle-income countries: a scoping review on genetics

MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer

Genetic knowledge and attitudes towards genetic testing among final-year medical students at a public university in Ecuador

General practitioners’ (GPs) experience, attitudes and needs on clinical genetic services: a systematic review

The emergence of an ethical duty to disclose genetic research results: international perspectives

A Scoping Review of Attitudes and Experiences with Pharmacogenomic Testing among Patients and the General Public: Implications for Patient Counseling